Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits

NCT01734759 | Completed Phase 1

• 1 other identifier: 12-005823
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.

Conditions

Healthy

Keywords

medication palatability; medication taste

Outcome Measures

Primary Outcomes (1)

• Taste scores on the visual analog scale

  Medication taste scores on the visual analog scale before and after a medication tasting will be measured.

  Change from baseline in taste scores at 3 months

Study Arms (1)

Taste Test

EXPERIMENTAL

Drug: Taste Test

Interventions

Taste Test DRUG

Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested. Medications to be sampled and the corresponding dose of the test dose are: * Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg * Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg * Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg * Steroids: prednisolone 1.5 mg, prednisone 0.5 mg * H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg

Taste Test

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• subjects possess prescriptive authority (e.g. MD, nurse practitioner, physician's assistant, medication therapy management pharmacists)
• subjects have prescribed at least one of the study medications from one of the medication classes to pediatric patients at an outpatient clinic in the three months preceding the study

You may not qualify if:

• subjects do not prescribe any of the tested medications
• subject has an allergy to all of the study medications
• subject is pregnant or breastfeeding
• subject has a medical condition that prevents them from being involved in the taste test
• Participants are advised to be within or accessible to the Rochester, MN area during study recruitment and accessible afterwards via mail, email or fax.

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Study Officials

• Bernard Lee, PharmD, RPh

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

• Ole J Olson, Pharm.D., BCPS

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

• Michelle J LoTurco, Pharm.D.

  Mayo Clinic

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: November 17, 2012
• First Posted: November 28, 2012
• Study Start: November 1, 2012
• Primary Completion: January 1, 2013
• Study Completion: January 1, 2013
• Last Updated: October 21, 2013

Record last verified: 2013-10

Locations

US (1)